Innovation through evidence | COVID 19

"If you ring up and start to apply pressure to them to say 'have you thought about giving my loved one drug A or drug B?' It might be helping them to get better but you might be encouraging them to do something that might hurt your loved one; so we have to do this with trials". This piece gets into one of the debates surrounding the treatment of COVID 19. What do we mean when we suggest people think outside the box? Do we still need to bother about ideas and principles such as evidence and data collection or should a more cavalier approach be taken to medicine in this unusual time? The following articles are discussed in this piece: "Incidence of thrombotic complications in critically ill ICU patients with COVID-19" https://doi.org/10.1016/j.thromres.2020.04.013 "Chloroquine diphosphate in two different dosages [...];" https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v1.full.pdf "Effectiveness of Hydroxychloroquine in Covid-19 Patients (Covid)" https://clinicaltrials.gov/ct2/show/NCT04328272 "Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19" https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ Presented by Desiree Chappell with Monty Mythen. Thank you to our sponsor Edwards Lifesciences. Edwards clinical education (ECE): https://www.edwards.com/clinicaleducation